- Home
- EVAX vs POAI Comparison
EVAX vs POAI Comparison
Compare EVAX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- POAI
- Stock Information
- Founded
- EVAX 2008
- POAI 2002
- Country
- EVAX Denmark
- POAI United States
- Employees
- EVAX N/A
- POAI N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- POAI Industrial Specialties
- Sector
- EVAX Health Care
- POAI Health Care
- Exchange
- EVAX Nasdaq
- POAI Nasdaq
- Market Cap
- EVAX 8.7M
- POAI 8.5M
- IPO Year
- EVAX 2021
- POAI N/A
- Fundamental
- Price
- EVAX $2.41
- POAI $1.57
- Analyst Decision
- EVAX Strong Buy
- POAI Hold
- Analyst Count
- EVAX 2
- POAI 1
- Target Price
- EVAX $11.00
- POAI N/A
- AVG Volume (30 Days)
- EVAX 250.1K
- POAI 3.7M
- Earning Date
- EVAX 10-31-2024
- POAI 11-12-2024
- Dividend Yield
- EVAX N/A
- POAI N/A
- EPS Growth
- EVAX N/A
- POAI N/A
- EPS
- EVAX N/A
- POAI N/A
- Revenue
- EVAX $3,295,000.00
- POAI $1,484,223.00
- Revenue This Year
- EVAX $4,845.21
- POAI N/A
- Revenue Next Year
- EVAX $30.30
- POAI $569.48
- P/E Ratio
- EVAX N/A
- POAI N/A
- Revenue Growth
- EVAX N/A
- POAI N/A
- 52 Week Low
- EVAX $2.38
- POAI $0.55
- 52 Week High
- EVAX $68.05
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- EVAX 23.50
- POAI 62.64
- Support Level
- EVAX $2.38
- POAI $1.16
- Resistance Level
- EVAX $3.90
- POAI $2.37
- Average True Range (ATR)
- EVAX 0.51
- POAI 0.42
- MACD
- EVAX -0.05
- POAI 0.01
- Stochastic Oscillator
- EVAX 2.72
- POAI 30.94
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.